Intuitive Surgical Shares Drop on Unchanged Procedure Guidance Despite Q2 Beat
Intuitive Surgical shares tumbled after the company maintained its full-year procedure growth guidance, signaling potential deceleration in robotic surgery demand despite a strong second-quarter earnings beat.
Intuitive Surgical shares fell approximately 14 percent to $345.42 following the release of its second-quarter 2026 earnings report on July 16. The drop occurred even as the medical robotics pioneer reported a 19 percent increase in revenue to $2.89 billion and non-GAAP net income of $1 billion, or $2.80 per diluted share.
Investors focused on the company’s decision not to raise its full-year guidance for da Vinci procedures, which remains at 13.5 percent to 15.5 percent growth. This range would represent the slowest expansion rate for the company’s core metric in several years, raising concerns about long-term demand.
Operationally, the quarter showed continued expansion. The company placed 468 da Vinci surgical systems, including 246 of the newer da Vinci 5 models, driving the total installed base to 11,710 systems as of June 30. Worldwide procedures grew approximately 15 percent year over year, and the company repurchased 0.9 million shares for $380 million.
The sell-off also reflects broader anxiety in the medical device sector. Earlier in the week, HCA Healthcare trimmed its full-year outlook, implying a reduction in overall surgical volumes and pressuring peer stocks. While Intuitive Surgical is still posting growth, the market is penalizing any sign of deceleration.
Valuation and Technical Pressures
At the close of trading on July 16, Intuitive Surgical traded at around 46 times forward earnings, a significant premium to the broader market. Although this represents a discount from historical multiples near 60 times earnings, investors are increasingly comparing the company to diversified peers like Medtronic and Boston Scientific, which command far lower valuations.
The stock’s technical posture has also deteriorated. Shares recently broke below their 200-week simple moving average of $411.89, a reliable support level during the 2023 to 2025 uptrend. With the weekly relative strength index at 35.97, its lowest level since the 2022 bear market, momentum remains firmly with sellers.
Despite the sharp decline, analysts maintain a moderate buy consensus with an average price target of $530.92. For patient investors, the nearly 50 percent implied upside suggests the market’s reaction to slower, but still positive, growth may present a strategic entry point.
